title: Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues.
abstract: The metastasis suppressor gene KAI1 was identified by its ability to inhibit the formation of pulmonary metastases in experimental models for prostatic carcinoma. Down-regulation of this gene may be correlated with the invasive phenotype in melanomas and colon and bladder carcinomas and with the metastatic phenotype in carcinomas of the lung, breast, prostate, and pancreas. The goal of our study was to establish an immunohistochemical method to detect KAI1 expression in archival tissues. Using cell lines with known KAI1 levels and paraffin-embedded KAI1 positive tissues as controls, we observed strong membrane staining in lymphoid follicular centers and squamous epithelia. We then demonstrated the utility of our assay by studying KAI1 expression in 34 lymphoid and 57 squamous lesions. All eight reactive lymph nodes were KAI1 positive. In contrast, three of 13 follicular small cleaved and five of 13 diffuse large cell lymphomas were KAI1 negative. Seventy-nine percent (37 of 47) of invasive squamous cell carcinomas from the lung (n = 15), head and neck (n = 18), and cervix (n = 14) showed extensive KAI1 down-regulation. Loss of KAI1 expression was also found in a subset of 10 high-grade cervical dysplasias. Our data show that (i) immunohistochemistry is a suitable technique for evaluating KAI1 expression in archival tissues; (ii) KAI1 was not expressed in a subset of both low-grade and high-grade lymphomas; and (iii) there was extensive down-regulation of KAI1 in squamous cell carcinomas, suggestive of an important role of the gene in the suppression of invasion in these malignancies.
authors.affiliation: Nuffield Department of Pathology and Bacteriology,* University of Oxford, England. joseph.geradts@ndp.ox.ac.uk
authors.forename: J
authors.initials: J
authors.lastname: Geradts
authors.forename: R
authors.initials: R
authors.lastname: Maynard
authors.forename: M J
authors.initials: MJ
authors.lastname: Birrer
authors.forename: D
authors.initials: D
authors.lastname: Hendricks
authors.forename: S L
authors.initials: SL
authors.lastname: Abbondanzo
authors.forename: K M
authors.initials: KM
authors.lastname: Fong
authors.forename: J C
authors.initials: JC
authors.lastname: Barrett
authors.forename: D P
authors.initials: DP
authors.lastname: Lombardi
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis*; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D015536:Down-Regulation; D005260:Female; D016147:Genes, Tumor Suppressor; D006258:Head and Neck Neoplasms / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D051861:Kangai-1 Protein; D008175:Lung Neoplasms / Q000378:metabolism; D008223:Lymphoma / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D011518:Proto-Oncogene Proteins; D051381:Rats; D016160:Retinoblastoma Protein / Q000378:metabolism; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C497688:CD82 protein, human; C497690:Cd82 protein, rat; D019941:Cyclin-Dependent Kinase Inhibitor p16; D051861:Kangai-1 Protein; D008562:Membrane Glycoproteins; D011518:Proto-Oncogene Proteins; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53